Skip to content

    Diabetes Health Center

    Font Size

    Drug May Treat Newly Diagnosed Type 1 Diabetes

    Study Shows Teplizumab May Preserve Function of Body's Insulin-Producing Cells
    WebMD Health News
    Reviewed by Laura J. Martin, MD

    June 28, 2011 (San Diego) -- The experimental drug teplizumab shows promise for delaying the progression of type 1 diabetes in people newly diagnosed with it, researchers say.

    In a study of 513 patients with type 1 diabetes, the drug failed to reach its primary goal of substantially improving blood sugar control and reducing the amount of insulin needed.

    But teplizumab appeared to preserve the function of the body's own insulin-producing beta cells in the pancreas, reports Nicole Sherry, MD, director of the diabetes center at the Massachusetts General Hospital for Children in Boston.

    "Preserving your own beta cell function is far better than relying on insulin [injections or a pump]," says Kevan Herold, MD, a Yale University endocrinologist who is heading another study of teplizumab.

    "Beta cells make the right amount of insulin at the right place and the right time," he tells WebMD. "They turn it off when you don't need it, and turn it on when you do need it."

    Sherry and Herold reporting being consultants to MacroGenics, which is developing teplizumab.

    The findings were simultaneously reported online in The Lancet and here at the American Diabetes Association meeting.

    Teplizumab vs. Placebo

    Type 1 diabetes is a disease in which the body's immune system attacks and destroys the insulin-producing beta cells of the pancreas.

    The study involved people ages 8 to 35 who were diagnosed with type 1 diabetes no more than 12 weeks before entering the study.

    Patients were given infusions of either placebo or of one of three regimens of teplizumab. After six months, the treatment was repeated.

    After one year, a similar percentage of people in each group -- about 20% -- had better blood sugar control and needed less insulin. But 5% of participants who received teplizumab no longer needed insulin at the end of one year, compared to none of those who received a placebo, Sherry says.

    Further researched showed that 40% of patients who received the highest dose of the drug had better beta cell preservation, compared with 28% of those in the placebo group.

    Younger patients, especially children ages 8 to 11, experienced the greatest gains in beta cell function, she says.

    Today on WebMD

    Diabetic tools
    Symptoms, diagnosis, treatment, and more.
    woman flexing muscles
    10 strength training exercises.
    Blood sugar test
    12 practical tips.
    Tom Hanks
    Stars living with type 1 or type 2.
    kenneth fujioka, md
    Can Vinegar Treat Diabetes
    Middle aged person
    jennie brand miller

    Prediabetes How to Prevent Type 2 Diabetes
    type 2 diabetes
    food fitness planner